Table 2.

Results of hypothesis testing.

Categories	Variables	Options	Reimbursement decisions, No. (%)		Test	P-value
			Positive (n = 76)	Negative (n = 36)
Trial design characteristics	Primary endpoint	Only OS	8 (10.5)	11 (30.6)	Pearson's chi-squared test	0.001
		Only PFS	32 (42.1)	6 (16.7)
		Only ORR	23 (30.3)	6 (16.7)
		Other	10 (13.2)	7 (19.4)
		Two endpoints	3 (3.9)	6 (16.7)
	Phases	I	3 (3.9)	1 (2.8)	Fisher's exact test	0.043
		II	24 (31.6)	4 (11.1)
		III	49 (64.5)	31 (86.1)
	Blinded experiment	Yes	28 (36.8)	16 (44.4)	Pearson's chi-squared test	0.442
		No	48 (63.2)	20 (55.6)
	Control group	Yes	53 (69.7)	28 (77.8)	Pearson's chi-squared test	0.374
		No	23 (30.3)	8 (22.2)
	Randomization	Yes	54 (71.1)	28 (77.8)	Pearson's chi-squared test	0.453
		No	22 (28.9)	8 (22.2)
Clinical outcomes	HROS data availability	Yes	30 (39.5)	19 (52.8)	Pearson's chi-squared test	0.185
		No	46 (60.5)	17 (47.2)
	Risk benefit in OS	Yes	17 (22.4)	18 (50.0)	Pearson's chi-squared test	0.011
		No	13 (17.1)	1 (2.8)
		Missing	46 (60.5)	17 (47.2)	/	/
	Magnitude of risk benefit in OS	HROS, median (interquartile range)	0.680 [0.530–0.747]	0.625 [0.428–0.743]	Two-sample t test	0.627
	HRPFS data availability	Yes	41 (53.9)	18 (50.0)	Pearson's chi-squared test	0.696
		No	35 (46.1)	18 (50.0)
	Risk benefit in PFS	Yes	37 (48.7)	16 (44.4)	Pearson's chi-squared test	1.000
		No	4 (5.3)	2 (5.6)
		Missing	35 (46.1)	18 (50.0)	/	/
	Magnitude of risk benefit in PFS	HRPFS, median (interquartile range)	0.377 [0.280–0.563]	0.588 [0.280–0.735]	Two-sample t test	0.087
	Magnitude of survival benefit	Survival benefit for mOS, median	2.6 [1.875–5.875]	4.95 [1.430-6.680]	Mann-Whitney U Test	0.545
		Survival benefit for mPFS, median	5.00 [2.075–6.975]	2.10 [0.080–8.075]	Mann-Whitney U Test	0.189